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INTRODUCTION
Human epidermal growth factor receptor 2 (HER2) over-
expression or amplification has been shown to be associated
with a poor prognosis in women with breast cancer (1). Fur-
thermore, trastuzumab, a humanized monoclonal antibody
directed against HER2 protein, has been shown to be active
against metastatic breast cancer (MBC) overexpressing HER2
(2). In combination with standard chemotherapy, trastuzum-
ab has been found to produce greater response rates and pro-
long survival in MBC (3). In vitro, HER2 overexpression con-
fers increased resistance to paclitaxel in breast cancer cells,
while HER2 degradation increases docetaxel-induced apop-
tosis (4). In a pivotal randomized phase III trial (5), response
rate to paclitaxel was significantly higher in MBC patients
when HER2 was downregulated by trastuzumab. HER2
overexpression is also believed to be associated with the effi-
cacy of taxane-based chemotherapy in women with MBC,
and trastuzumab may sensitize HER2-overexpressing breast
cancer cells to taxanes and result in additive and/or syner-
gistic interactions (6). Common toxicities associated with 3-
weekly infusions include neutropenic fever, stomatitis and
arthralgia/myalgia, but by administering lower doses of tax-
anes more frequently, these toxic effects might be reduced
while maintaining dose intensity (7). A recent result of a com-
parative phase III study on weekly paclitaxel and 3-weekly
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Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients
with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of
HER2/neu Amplification as a Predictive Factor for Efficacy
We evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab as first-
line chemotherapy in women with HER2-overexpressing metastatic breast cancer
(MBC), and we investigated the prognostic factors including magnitude of HER2/neu
amplification in this population. We analyzed 54 patients with HER2-overexpressing
MBC that were treated with weekly paclitaxel plus trastuzumab as first-line chemo-
therapy from February 2004 to December 2006. At a median follow-up of 28 months,
median time to progression (TTP) was 16.6 months (95% CI, 9.4 to 23.7 months)
and median overall survival was 25.6 months (95% CI, 21.8 to 27.3 months). Ther-
apy was generally well tolerated, although three patients (5.5%) experienced rever-
sible, symptomatic heart failure. Of the 27 patients evaluable for the HER2 FISH,
patients with a HER2/CEP17 ratio of ≤4.0 had significantly shorter TTP than those
with a HER2/CEP17 ratio of >4.0 (10.8 vs. 23.2 months, P=0.034). A HER2/CEP17
ratio of >4.0 was identified as significant predictive factor of TTP by multivariate anal-
ysis (P=0.032). The combination of weekly paclitaxel plus trastuzumab as first-line
chemotherapy is an effective regimen in patients with HER2-FISH-positive MBC.
Furthermore, the magnitude of HER2 amplification is an independent predictive fac-
tor of TTP.
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paclitaxel showed the superiority of weekly administration
in terms of response rate, time to progression and survival (8).
However, by subgroup analyses, trastuzumab did not improve
paclitaxel efficacy in HER2 normal MBC. Therefore, week-
ly paclitaxel regimens represent a valuable therapeutic option
for women with MBC, and weekly paclitaxel with trastuzum-
ab in MBC with HER2 overexpression has produced promis-
ing results (8-12). 
Although trastuzumab is active in patients with HER2-
overexpressing MBC, its activity is consistently higher in sub-
sets of patients with an immunohistochemistry (IHC) score
of 3+ or gene amplification by fluorescence in-situ hybridi-
zation (FISH) than in those with an IHC score of 2+ (5, 8,
12). These findings suggest that response to trastuzumab is
substantially dependent on the magnitude of HER2 ampli-
fication.
In this study, we evaluated the efficacy and safety of week-
ly paclitaxel plus trastuzumab in women with HER2-over-
expressing MBC. In addition, we investigated whether the
magnitude of HER2 amplification is an independent predic-
tor for survival.
MATERIALS AND METHODS
Study population and definition of HER2 positivity
We reviewed the records of patients with HER2-overex-
pressing MBC who had been treated with weekly paclitaxel
plus trastuzumab as first-line chemotherapy since 2004 in
our hospitals according to the prewritten protocol. Eligibil-
ity criteria included: 1) age ≥18 yr with histologically doc-
umented metastatic or relapsed HER2 positive breast can-
cer, 2) no prior chemotherapy in metastatic or relapsed set-
ting, 3) at least one measurable or evaluable lesion, 4) ade-
quate cardiac function evaluated by echocardiography (left
ventricular ejection fraction (LVEF) ≥50%) and no prior
history of uncontrolled arrhythmia or significant cardiac dis-
ease, 5) Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0-2, and 6) adequate hematologic, hepat-
ic and renal function. 
Standardized HER2 staining was evaluated by two pathol-
ogists in each hospital unaware of clinical information. HER2
IHC results using CB-11 antibody (Novocastra Laboratories,
Vision BioSystems, Inc., Norwell, MA, U.S.A.) were scored
as 0 when no specific membrane staining was apparent with-
in a tumor and positive when any staining of the tumor cell
membranes was observed above the background level. Posi-
tive samples were classified semiquantitatively using a 0, 1+,
2+, and 3+ scale, based on their staining intensities. When
the staining was heterogeneous, the highest staining inten-
sity was used as the final immunohistochemical result. FISH
was performed using PathVysionTM HER2 DNA probe kits
(PathVysion; Vysis, Stuttgart-Fasanenhof, Germany) and ana-
lyzed as previously described (13). HER2 positivity was de-
fined as an intensity of 3+ by IHC or as gene amplification
by FISH. This study was approved by the Institutional Re-
view Board at Seoul National University Hospital.
Treatment 
Paclitaxel plus trastuzumab chemotherapy was adminis-
tered either at Seoul National University Hospital or at Seoul
National University Bundang Hospital. Trastuzumab was
administered intravenously (IV) over 90 min at the loading
dose of 4 mg/kg on day 1 followed by weekly doses of 2 mg/kg
over 30 min. Paclitaxel was administered at 80 mg/m2 IV by
1-hr infusion, following trastuzumab administration every
week. Treatment was maintained using this weekly schedule
until disease progression or prohibitive toxicity occurred. Pacli-
taxel treatment was maintained up to 12 cycles at the longest
for the patients who were tolerable and did not show progres-
sion during treatment, however, paclitaxel was allowed to stop
after 6 cycles of treatment when maximal benefit of response
obtained according to the investigator’s decision and these
patients continued to receive single-agent trastuzumab until
disease progression. Premedications consisted of dexametha-
sone 10 mg IV, cimetidine 300 mg IV, and pheniramine 50
mg IV administered 30 to 60 min before paclitaxel infusion.
Paclitaxel was administered at full dose if the absolute neu-
trophil count was >1,500/μ L and the platelet count was
>100,000/μ L. Doses of paclitaxel were reduced in decrements
of 10 or 20 mg/m2 if grade 2 or 3 hematologic or nonhema-
tologic toxicities occurred and skipped if grade 4 toxicities
occurred. Patients who were responsive to paclitaxel but requi-
red discontinuation because of toxicity continued to receive
single-agent trastuzumab until disease progression. Trastu-
zumab was permanently discontinued in patients with symp-
tomatic cardiac events (National Cancer Institute Common
Toxicity Criteria [NCI-CTC], grade 3 or 4).
Response and toxicity assessment
Response assessment was planned every 12 weeks of treat-
ment, according to the Response Evaluation Criteria in Solid
Tumor (RECIST) criteria (14). Non-hematologic toxicity and
hematologic toxicity evaluations were performed every 2 weeks
and were graded according to NCI-CTC version 3.0. Labo-
ratory assessments of blood chemistry and chest radiography
were carried out every 4 weeks. LVEF was assessed by echocar-
diography every 12 weeks and when clinically significant car-
diac symptoms developed.
Statistical analysis
Patients were considered evaluable for the response if they
had received at least 12 weeks of treatment or progressive di-
sease at any time. Patients were considered evaluable for tox-912 H.-S. Han, J.-S. Kim, J.H. Park, et al.
icity analysis if they had received at least 2 weeks of treatment.
Duration of response was defined as the time between first
response and disease progression. Time to progression (TTP)
was defined as the time from treatment start to disease pro-
gression, and was censored at the last date of contact for those
that did not experience disease progression. Survival was de-
fined as the time from treatment start until death, and was
censored at the date of last contact for those that remained
alive. TTP and survival were analyzed using the Kaplan-Meier
method and compared using log-rank tests. Multivariate anal-
ysis using Cox regression model was performed to investigate
the association between clinical outcomes (TTP and survival)
and clinical variables, HER2/CEP17 ratio by FISH. The fol-
lowing were regarded as potential explanatory variables; age,
hormone receptor status, number of metastatic sites, domi-
nant metastatic site, HER2/CEP 17 ratio by FISH, and sub-
sequent central nervous system (CNS) metastases after treat-
ment initiation. P values of 0.05 or less were considered to
indicate statistical significance. All statistical analyses were
performed using SPSS for Windows software, version 15.0
(SPSS Inc, Chicago, IL, U.S.A.).
RESULTS
Patient characteristics
A total of 54 patients with HER2-overexpressing MBC
who were treated with weekly paclitaxel plus trastuzumab
registered at Seoul National University Hospital (n=42) or
Seoul National University Bundang Hospital (n=12) between
February 2004 to December 2006. Seven patients had already
received taxanes in neoadjuvant or adjuvant setting; the medi-
an interval from prior taxane to weekly paclitaxel in the study
was 29.5 months (range, 14.8-52.1 months). Baseline char-
acteristics of these patients are summarized in Table 1. 
Efficacy and survival
A total of 1,647 weekly infusions of paclitaxel plus trastu-
zumab and subsequently 613 weekly infusions of maintenance
trastuzumab single agent in 14 patients were administered.
The median number of weeks of paclitaxel plus trastuzum-
ab was 24.8 (range, 2-64) and subsequent trastuzumab was
35.8 (range, 10-104), and the median delivered dose-inten-
sity for paclitaxel was 70 mg/m2/week, which equated to a
median relative dose-intensity of 87.5%. Fifty one (94.4%)
of the 54 enrolled patients received at least 12 weeks of treat-
ment. Two patients died of rapid disease progression before
8th week of treatment and one patient was lost to follow up
before response assessment. Fifty-one (94.4%) of the 54 en-
rolled patients were assessable for the response; two patients
with only non-measurable bone metastasis were not assessable
for the response and one patient was lost to follow up before
response assessment, two patients died of rapid disease pro-
gression were evaluated as progressive disease. Of the 51 asse-
ssable patients, best objective responses included complete
response in 9 (17.7%) and partial response in 32 (62.7%);
an overall response rate (ORR) of 80.4% (95% CI, 70.9 to
92.5%). Stable disease was observed in 6 assessable patients
(11.8%), and only 4 patients (7.8%) experienced disease pro-
gression without any period of at least stable disease while
on the protocol therapy (Table 2). In this analysis, a total of
30 patients progressed on treatment; the brain was the major
site of progressive disease and occurred in 13 patients (25.5%
ECOG PS, Eastern Cooperative Oncology Group performance status;
ER, estrogen receptor; PR, progesterone receptor.
No. of patients (n=54)
Variables
No. %
Age (yr)
Median 47.5 (range: 30-77)
ECOG PS
0 35 64.8
1 15 27.8
2 4 7.4
Hormone receptor status
ER and/or PR positive 21 38.9
ER and PR negative 33 61.1
Disease status at diagnosis
Relapsed 39 72.2
Initially metastatic 15 27.8
No. of metastatic sites
1 25 46.3
2 21 38.9
≥3 8 14.8
Metastatic sites
Lung, pleural effusion 29 53.7
Liver 18 33.3
Bone 16 29.6
Soft tissue 26 48.1
Prior therapy for breast cancer
Neo/adjuvant chemotherapy 41 75.9
Anthracyclines 26 48.1
Taxanes 7 13.0
Adjuvant hormonal therapy 11 20.4
Adjuvant radiotherapy 16 29.6
Table 1. Characteristics of the patients
Evaluable patients (n=51)
Responses
No. %
Response
Complete response 9 17.7
Partial response 32 62.7
Stable disease 6 11.8
Progressive disease 4 7.8
Overall response rate  41 80.4
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of assessable patients). At a median follow-up of 28 months,
median TTP was 16.6 months (95% CI, 9.4 to 23.7 months)
(Fig. 1A) and median overall survival was 25.6 months (95%
CI, 21.8 to 27.3 months) (Fig. 1B). 
Safety
All 54 patients who received at least 2 weeks of therapy
were assessable for toxicity. In general, the treatment was well
tolerated, and the majority of adverse events were of mild to
moderate severity (Table 3). Serious hematologic toxicities
were infrequent, with grade 3 leukopenia in 11% and grade
3 neutropenia in 22% of patients. However, there were 35
patients (64.8%) who needed dose reduction due to grade 2
or 3 neutropenia. No neutropenic fever occurred. The most
common non-hematologic toxicities were peripheral neuropa-
thy and onycholysis. Non-neutropenic infections were obser-
ved in 3 patients (6%). One patient suffered from pneumo-
nia after 13 months of treatment and chemotherapy was del-
ayed while antibiotics were administered. Another patient
had pulmonary tuberculosis but continued on paclitaxel plus
trastuzumab therapy with anti-tuberculosis medication. The
third patient withdrew from treatment because of a grade 3
chest wall infection. Grade 3 elevations in transaminases were
believed to be associated with underlying fatty liver disease.
Paclitaxel was discontinued in seven patients, because of peri-
pheral neuropathy in 5, onycholysis in 1, and a chest wall in-
fection in 1. 
The major adverse event associated with trastuzumab was
cardiac dysfunction in patients previously exposed to anthra-
cyclines. Seventeen patients developed grade 1 LV systolic
dysfunction, and one patient developed grade 2 LV systolic
dysfunction. For 18 patients who showed grade 1 or 2 LV sys-
tolic dysfunction, the cardiac function has been improved after
discontinuation of trastuzumab and the trastuzumab treat-
ment resumed after median 6 weeks. Symptomatic heart fail-
ure occurred in 3 patients (6%) who had received anthracy-
cline-based adjuvant chemotherapy. One patient who had
been administered a lower cumulative dose of doxorubicin
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Fig. 1. (A) Time to progression (TTP), (B) Overall survival (OS).
A
B
AST, aspartate aminotransferase; ALT, alanine aminotransferase; LV, left
ventricular
Grade 1 Grade 2 Grade 3 Grade 4
Toxicities
No. % No. % No. % No. %
Hematological
Leukopenia 26 48 18 33 6 11 0 0
Neutropenia 12 22 23 43 12 22 0 0
Anemia 14 26 9 17 0 0 0 0
Thrombocytopenia 2 4 2 4 0 0 0 0
Non-hematological
Neuropathy 8 15 4 7 3 6 0 0
Onycholysis 2 4 7 13 1 2 0 0
Infection 0 0 1 2 2 4 0 0
Increased AST/ALT 16 30 1 2 1 2 0 0
LV dysfunction 17 31 1 2 3 6 0 0
Table 3. Hematological and non-hematological toxicities (n=54)
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Fig. 2. Time to progression (TTP) of patients with a HER2/CEP17
ratio ≤4.0 (dotted line) or >4.0 (continuous line). A statistically sig-
nificant difference was observed (10.8 and 23.2 months, respec-
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(180 mg/m2) than the others had received adjuvant radiother-
apy to the left breast. All 3 patients improved on standard
treatments for congestive heart failure. 
Clinical outcomes and HER2/CEP17 ratio by FISH
In the 27 patients with FISH data available, HER2/CEP17
ratios varied from 0.95 to 16.2. Patients with a lower HER2/
CEP17 ratio (less than 4.0) had a significantly shorter TTP
than those with a higher ratio (10.8 vs. 23.2 months; P=0.034)
(Fig. 2, 3). Although a search for predictive factors of survival
failed to yield a significant result for any of the investigated
variables, multivariate analysis for factors that predict TTP
resulted in statistical significance for a HER2/CEP17 ratio
of >4.0 (P=0.032) (Table 4).
DISCUSSION
In this study, we confirmed the efficacy and safety of week-
ly paclitaxel plus trastuzumab in women with HER2-over-
expressing MBC. We obtained an ORR of 80.4% and only
4 (7.8%) of the patients experienced progressive disease as
best clinical response. Moreover, the majority of adverse events
were mild to moderate in severity and all proved reversible
with supportive care. Although it is lower than previous stud-
ies (8, 12), the dose intensity of weekly paclitaxel was 87.5%,
demonstrating the tolerability of this regimen.
Fig. 3. The FISH patterns of HER2/neu gene. The FISH test “high-
light” the HER2 genes inside the cell, making them appear as flu-
orescent signals (dots) so they may be accurately counted. Path-
Vysion
� FISH also measures the number of copies of chromosome
17 in the cell. Since the HER2 gene resides on chromosome 17, this
adds several measures of control to the test. After counting the HER-
2 and Chromosome 17 signals in 20 nuclei, the ratio of HER2 to
Chromosome 17 is calculated. (A) Nuclei with low HER2/neu gene
amplification (a HER2/CEP17 ratio of <2.0). (B) Nuclei with inter-
mediate HER2/neu gene amplification (a HER2/CEP17 ratio of 2.0-
4.0). (C) Nuclei with high HER2/neu gene amplification (a HER2/
CEP17 ratio of >4.0).
A
C
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Optimizing the dosing schedule to maximize therapeutic
efficacy, while maintaining a favorable toxicity profile, remains
an important treatment goal in MBC, and weekly dosing of
paclitaxel at a lower dose rather than adopting the standard
3-weekly regimen might better achieve this goal. Several stu-
dies have supported weekly paclitaxel as an active regimen in
MBC, even when patients were heavily pretreated, had refrac-
tory disease, were elderly, or had a poor performance status
(15, 16). Furthermore, the encouraging results obtained dur-
ing single agent trials on weekly paclitaxel in MBC provide
a basis for assessing these schedules in combination regimens
(17, 18). In these previous studies, hematologic and nonhema-
tologic toxicities were infrequent and dependent on the dose
and weekly regimen selected. Based on the above-mentioned
studies, weekly paclitaxel and trastuzumab was evaluated in
several phase II trials and recent phase III trial involving MBC
patients with HER2-overexpressing tumors (8, 10, 12). The
Hellenic Cooperative Oncology Group evaluated weekly pac-
litaxel plus trastuzumab as first line therapy in 34 patients
with HER2-overexpressing MBC, and achieved an ORR of
62% and a median TTP of 9 months (10). In addition, a re-
cently reported randomized phase II trial also evaluated the
activity of weekly paclitaxel vs. paclitaxel plus trastuzumab
for the treatment of patients with HER2-overexpressing MBC,
and achieved an ORR of 75% and a median TTP of 10 mon-
ths (12). One of the interesting findings obtained during this
study was that weekly paclitaxel plus trastuzumab was found
to be significantly more active in those with an IHC score
of 3+ than in those with an IHC score of 2+ (ORR 84.5%
vs. 47.5%; P<0.001 and TTP 369 days vs. 272 days; P=
0.030), which agrees with our data (ORR 80.4% and TTP
16.6 months). 
There are four substantial differences between previous stu-
dies on weekly paclitaxel plus trastuzumab and the present
study. First, in the present study, HER2 positivity was strictly
defined as 3+ by IHC or as amplification by FISH, whereas
other studies determined HER2 overexpression based on IHC
criteria alone and include the IHC score of 2+ patients. Thus,
the higher level of HER2 overexpression adopted in the pre-
sent study might explain the better responses and longer TTP
obtained. Second, we included more hormone receptor (HR)
negative patients who are known to have a poorer prognosis
than HR positive patients, and although no significant dif-
ference was observed, HR negative patients tended to have
shorter TTPs and overall survivals than HR positive patients
in the present study. Third, the incidence of symptomatic
heart failure was higher in the present study, although these
cardiac dysfunctions were all reversed by standard cardiac me-
dications. Because of longer TTP of this study, longer treat-
ment duration of trastuzumab might be one of the possible
reasons for explanation. Cardiotoxicity is one of the most seri-
ous toxicities associated with trastuzumab, as previous major
trials have shown (19). Thus, the cardiac functions of patients
administered trastuzumab should be carefully monitored, es-
pecially those with history of anthracycline use or radiother-
apy to the left breast. In the present study, we monitored car-
diotoxicity by regular echocardiography, and found seventeen
patients with grade 1 LV systolic dysfunction and one patient
with grade 2 LV systolic dysfunction. The cardiac function
was improved after discontinuance of trastuzumab and the
trastuzumab treatment could be resumed after median 6 weeks
according to our institutional guideline in all asymptomatic
patients if the LVEF is ≥50%. Lastly, there are several dif-
ferences in non-cardiac toxicities. Most of the patients expe-
rienced neutropenia without fever. Grade 1, 2, and 3 neutro-
penia occurred in 22%, 43%, and 22% of patients, respec-
tively. These results are higher than previous Western stud-
ies using even higher dose of paclitaxel 90 mg/m2 which sho-
wed 18-29% of grade 1/2 neutropenia and 6-12.7% of grade
3/4 neutropenia (9, 10). In our study, grade 1, 2, and 3 periph-
eral sensory neuropathy occurred in 15%, 7%, and 6%, res-
pectively. The occurrence of peripheral sensory neuropathy
was lower than previous studies using weekly paclitaxel 90
mg/m2 plus trastuzumab for median 25 weeks (range 11-78
weeks) in metastatic breast cancer. There are several reasons
to explain the lower incidence of neuropathy. Our study used
planned dose of 80 mg/m2 weekly paclitaxel, which was less
*The ratio is for HER2/CEP17 signals according to PathVysion guidelines;
� CNS metastases were defined as one or more brain metastases or as
leptomeningeal carcinomatosis.
NR, not reached; CEP17, chromosome 17 centromere; CNS, central ner-
vous system.
Time to progression
Variables
Overall survival
Months 
Multivari-
ate P
Univari-
ate P
Months
Univari-
ate P
Multi-
variate P
Age (yr) 0.306 0.136 0.484 0.990
≤40 12.4 23.5
41-50 16.6 25.6
51-60 17.7 23.4
≥61 NR NR
Hormone receptor  0.969 0.082 0.143 0.767
status   
Positive 18.0 NR
Negative 16.6 23.4
No. of metastatic  0.550 0.418 0.722 0.768
sites
1-2 16.6 25.6
≥3 18.4 24.5
Dominant sites 0.582 0.439 0.807 0.769
Visceral 16.6 25.6
Non-visceral 17.7 23.6
HER2/CEP17 ratio* 0.034 0.032 0.420 0.757
≤4.0 10.8 NR
>4.0 23.2 NR
Site of progression 0.635 0.239 0.247 0.768
CNS metastases
� 7.7 23.2
Other sites 10.4 23.5
Table 4. Univariate and multivariate analysis for time to progres-
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than 90 mg/m2 in previous studies, and we followed the dose
reduction schedule described in the method section if the pat-
ients experienced grade 2 or 3 hematologic or non-hemato-
logic toxicities. There were 35 patients (65%) who needed
dose reduction due to grade 2/3 neutropenia or grade 2 peri-
pheral sensory neuropathy. Consequently, the median deliv-
ered dose intensity of paclitaxel was 70 mg/m2/week, which
was lower than that of other studies and this is probably the
main reason for explaining less peripheral neuropathy in this
study. The median duration of treatment for paclitaxel was
similar with other studies. Although it is impossible to com-
pare the median cumulative dose of paclitaxel with other stu-
dies, the median cumulative dose of paclitaxel might be lower
than previous studies if we extrapolated our data using dura-
tion of treatment and dose intensity. In addition, the possi-
bility of underestimation due to a limitation of outcome re-
search is not excluded. Moreover, Korean patients have a ten-
dency to answer vaguely to the neuropathy directed questions.
Brain metastasis (BM) was the major site of progression in
the present study. HR negativity and HER2/neu expression
are considered to be independent risk factors of BM (20). Pat-
ients receiving trastuzumab as first-line therapy frequently de-
velop BM while responding to or with stable disease at other
disease sites. It has also been reported that trastuzumab is hi-
ghly effective at treating liver and lung metastasis in HER2-
overexpressing patients, though it is apparently ineffective
at treating or preventing BM (21), which is probably explain-
ed by its inability to cross the blood brain barrier (22). Since
one third of HER2-overexpressing patients with MBC devel-
oped BM despite effective trastuzumab treatment, new treat-
ment strategies based on lapatinib or CI-1033 and closer sur-
veillance may be warranted for these patients.
Several studies have shown that FISH is a better determi-
nant of trastuzumab eligibility and a better predictor of pro-
gnosis than IHC (23). Furthermore, one retrospective study
found that the magnitude of HER2 amplification might be
associated with a higher probability of achieving an objective
response (24). However, no significant FISH cut-off value was
identified in the previous study. We used the PathVysion as-
say, which included a chromosome-17 probe in a dual-color
format. Tumors with a ratio of ≥2.0 HER2 gene copies vs.
CEP17 are considered to show HER2 amplification (25). In
the present study, when patients were stratified about a HER-
2/CEP17 ratio cut-off of 4.0, a statistically significant differ-
ence in TTP was found between the two groups. In addition,
a HER2/CEP17 ratio of >4.0 was found to significantly pre-
dict TTP by multivariate analysis. Accurate assessment of
HER2 status is essential for determining whether patients
are candidates for trastuzumab therapy. Although the present
study was based on relatively small number of patients, par-
ticularly for HER2 amplification analysis, we suggest that
the role of quantitative HER2 gene amplification for predict-
ing efficacy to paclitaxel plus trastuzumab should be consid-
ered in order to define an optimal FISH scoring system for
the selection of patients that might benefit from trastuzum-
ab-based treatment.
In conclusion, weekly paclitaxel plus trastuzumab is an ac-
tive regimen in HER2-overexpressing (defined as 3+ by IHC
or as amplification by FISH) MBC patients. The present study
also suggests that not only HER2 amplification status but
also magnitude of HER2 amplification may be a predictive
factor for the efficacy of trastuzumab.
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